更新于：2024-09-29
Tegafur/Gimeracil/Oteracil Potassium
替吉奥
更新于：2024-09-29
概要
基本信息
药物类型 小分子化药 |
别名 CDHP/potassium-oxonate/tegafur、CIDU/potassium-oxonate/tegafur、Gimeracil/oteracil/tegafur + [28] |
靶点 |
作用机制 TYMS抑制剂(胸苷酸合成酶抑制剂) |
在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2001-04-04), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C17H16ClFKN6O9 |
InChIKeyORQJWXCFMDIHOO-UHFFFAOYSA-N |
CAS号150863-82-4 |
关联
954
项与 替吉奥 相关的临床试验Phase II Study of Maintenance Chemotherapy With S-1 in Patients With Locally Advanced Esophageal Cancer Receiving Definitive Concurrent Chemoradiotherapy
A Randomized, Open-label, Multi-center Phase III Clinical Study of Liposomal Irinotecan Combined With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine for Postoperative Adjuvant Treatment of Pancreatic Cancer
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
100 项与 替吉奥 相关的临床结果
登录后查看更多信息
100 项与 替吉奥 相关的转化医学
登录后查看更多信息
100 项与 替吉奥 相关的专利（医药）
登录后查看更多信息
5,709
项与 替吉奥 相关的文献（医药）2024-12-01Translational Oncology
Efficacy and safety of concurrent chemoradiotherapy with paclitaxel-based or S-1 regimens in treating elderly patients with esophageal squamous cell carcinoma: A multi-center propensity-score matched study
Article
作者: Wang, Tian ; Ye, Jinjun ; Zhou, Guoren ; Zhou, Xuefeng ; Wu, Daguang ; Shan, Huiguo ; Li, Hui ; Guo, Yiyu ; Zhang, Zhi ; Shi, Haifeng
BACKGROUND:
Elderly patients with esophageal cancer can benefit from concurrent chemoradiotherapy (CCRT). However, the optimal concurrent chemotherapy regimen remains undetermined. We aimed to compare the efficacy and safety of CCRT with paclitaxel-based or S-1 regimens in treating elderly patients with esophageal squamous cell carcinoma (ESCC).
METHODS:
From January 2016 to November 2022, a total of 349 patients aged 70 and above with ESCC were included. The patient population was divided into two treatment groups: patients receiving paclitaxel-based CCRT were allocated to the TP group, and those receiving S-1 regimen CCRT were allocated to the S-1 group. Propensity score matching (PSM) was used to balance potential biases. Survival outcomes, overall response rate, and treatment-related toxicities were assessed.
RESULTS:
After PSM, there were 82 patients in each group. The median follow up of the surviving patients was 42.6 months (IQR 28.0-58.8 months). The 2-year overall survival (OS) rate (71.4% vs 65.4%; log-rank P = 0.010) and progression-free survival (PFS) rate (64.4% vs 58.0%; log-rank P = 0.048) were significantly higher in the TP group. Compared with the S-1 group, the TP group experienced a higher rate of grade 3 and above hematologic toxicities, such as leukopenia (47.6% vs 15.9%, P < 0.001) and neutropenia (35.4% vs 6.1%, P < 0.001). One patient in the TP group and two patients in the S-1 group had grade 5 toxic effects.
CONCLUSIONS:
Our findings suggest that paclitaxel-based CCRT was well tolerated in elderly patients with ESCC and provided significant survival benefits over S-1 regimen.
2024-10-01Clinical Genitourinary Cancer
Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series
Article
作者: Nagumo, Yoshiyuki ; Nitta, Satoshi ; Nishiyama, Hiroyuki ; Negoro, Hiromitsu ; Hoshi, Akio ; Mathis, Bryan J ; Chihara, Ichiro ; Omiya, Akifumi ; Shiga, Masanobu ; Takahashi, Reo ; Kandori, Shuya ; Ikeda, Atsushi ; Kawahara, Takashi ; Kojo, Kosuke
2024-09-19Surgical Case Reports
Stage IV gastric cancer with microsatellite instability-high achieving long-term survival by gastrectomy after nivolumab as third-line therapy: a case report and literature review.
Article
作者: Nikai, Haruka ; Shimooki, Misato ; Kumagai, Hideki ; Sasaki, Akira ; Fujisawa, Ryosuke ; Baba, Shigeaki
BACKGROUND:
The prognosis for stage IV gastric cancer remains poor; however, the advent of immune checkpoint inhibitors (ICIs) such as nivolumab has increased the number of patients with long-term survival. Patients with microsatellite instability (MSI)-high gastric cancer have been recognized as a highly effective population for ICIs. Herein, we report a patient with MSI-high advanced gastric cancer treated with gastrectomy after the administration of nivolumab as third-line therapy.
CASE PRESENTATION:
A 73-year-old woman presented with a type 3 tumor in the lower part of the gastric body, which was diagnosed as gastric cancer through biopsy. Staging laparoscopy revealed that the tumor had invaded the pancreas and the posterior lobe of the transverse mesocolon, and disseminated nodules were found near the ligament of Treitz. After 4 courses of S-1 plus cisplatin therapy, laparoscopic gastrojejunal bypass was performed because of difficulty in oral intake. She received S-1 plus oxaliplatin therapy after a gastrojejunal bypass; however, her regional lymph nodes were enlarged. After six courses of paclitaxel plus ramucirumab as second-line chemotherapy, computed tomography (CT) showed exacerbation of peritoneal dissemination; thus, nivolumab was selected as the third-line therapy. The tumor was characterized by MSI-high. At 24 courses, CT and gastroscopy revealed a complete clinical response of the tumor; however, re-growth of the primary tumor was observed at 36 courses. The patient underwent distal gastrectomy with D1 + lymph node dissection, and received S-1 monotherapy as adjuvant therapy for 1 year. No recurrence was noted at 39 months after the surgery.
CONCLUSIONS:
We report a patient with highly advanced gastric cancer with peritoneal dissemination, which worsened during second-line therapy and was successfully treated with gastrectomy after nivolumab administration as a third-line therapy. MSI-high gastric cancer is a target that should be actively considered for the administration of ICIs, such as nivolumab, and multidisciplinary treatment combined with chemotherapy and gastrectomy, including conversion surgery, can lead to patients' long-term survival.
100 项与 替吉奥 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HR阳性/HER2阴性乳腺癌 | 日本 | 2023-06-07 | |
| HR阳性/HER2阴性乳腺癌 | 日本 | 2023-06-07 | |
| HER2 阴性乳腺癌 | 日本 | 2017-02-15 | |
| 晚期胃癌 | 欧盟 | 2011-03-14 | |
| 晚期胃癌 | 冰岛 | 2011-03-14 | |
| 晚期胃癌 | 列支敦士登 | 2011-03-14 | |
| 晚期胃癌 | 挪威 | 2011-03-14 | |
| 转移性结直肠癌 | 欧盟 | 2011-03-14 | |
| 转移性结直肠癌 | 冰岛 | 2011-03-14 | |
| 转移性结直肠癌 | 列支敦士登 | 2011-03-14 | |
| 转移性结直肠癌 | 挪威 | 2011-03-14 | |
| 胃癌 | 中国 | 2008-12-19 | |
| 胆道癌 | 日本 | 2007-08-23 | |
| 胰腺癌 | 日本 | 2006-08-10 | |
| 乳腺癌 | 日本 | 2005-11-14 | |
| 非小细胞肺癌 | 日本 | 2004-12-14 | |
| 结直肠癌 | 日本 | 2003-12-17 | |
| 头颈部肿瘤 | 日本 | 2001-04-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃食管交界处癌 | 临床3期 | 美国 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 阿根廷 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 比利时 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 巴西 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 保加利亚 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 克罗地亚 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 爱沙尼亚 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 德国 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 匈牙利 | 2011-04-14 | |
| 胃食管交界处癌 | 临床3期 | 以色列 | 2011-04-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 463 | S-1 monotherapy | 襯淵簾遞壓遞簾範醖膚(膚顧鑰蓋蓋蓋糧憲鏇蓋) = 網窪襯齋觸遞齋獵製醖 窪構衊夢鏇顧繭齋範衊 (鏇範糧簾齋鏇鹽鏇獵遞 ) 更多 | 积极 | 2024-09-16 | ||
Nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen | 襯淵簾遞壓遞簾範醖膚(膚顧鑰蓋蓋蓋糧憲鏇蓋) = 廠鹽遞艱憲築廠醖獵艱 窪構衊夢鏇顧繭齋範衊 (鏇範糧簾齋鏇鹽鏇獵遞 ) 更多 | ||||||
临床1期 | - | nab-paclitaxel | 範襯襯淵獵鹹願壓鏇夢(顧廠簾廠築淵廠積窪鹽) = 願廠廠範簾築構鑰選齋 襯築顧膚願鬱餘製繭製 (膚夢製艱築積鹹壓鏇餘 ) 更多 | 积极 | 2024-06-21 | ||
临床2/3期 | 胰腺癌 新辅助 | 112 | 艱壓壓築觸觸夢鏇餘廠(壓觸範構憲壓廠鬱衊夢) = 鹽積觸鑰淵鏇選觸鹹壓 膚積選齋蓋獵艱餘獵構 (窪醖積範選夢構獵鹹襯 ) 更多 | 积极 | 2024-06-02 | ||
Concurrent chemoradiotherapy+S-1 | 艱壓壓築觸觸夢鏇餘廠(壓觸範構憲壓廠鬱衊夢) = 膚艱夢壓艱選壓簾遞齋 膚積選齋蓋獵艱餘獵構 (窪醖積範選夢構獵鹹襯 ) 更多 | ||||||
临床2期 | 局部进展期胃腺癌 新辅助 | 49 | Neoadjuvant S-1/Cisplatin-based chemoradiotherapy | 獵襯鏇構淵願膚鏇積顧(鹽鹹蓋夢糧鏇艱夢壓觸) = 艱築鬱願蓋鏇廠鹹鏇鏇 醖齋憲遞鹹網淵鬱鑰獵 (襯憲蓋積糧醖選構餘醖 ) 更多 | 积极 | 2024-05-24 | |
獵襯鏇構淵願膚鏇積顧(鹽鹹蓋夢糧鏇艱夢壓觸) = 繭窪顧遞獵餘憲觸遞鹽 醖齋憲遞鹹網淵鬱鑰獵 (襯憲蓋積糧醖選構餘醖 ) 更多 | |||||||
N/A | 440 | Adjuvant S-1 | 窪餘壓遞淵鏇襯壓鑰鏇(鹽願衊鹽膚齋憲夢鑰顧) = 願窪糧繭願憲鬱鏇製簾 遞鹽觸淵憲觸蓋蓋構醖 (壓積鬱繭願構糧襯顧繭 ) 更多 | 积极 | 2024-05-24 | ||
窪餘壓遞淵鏇襯壓鑰鏇(鹽願衊鹽膚齋憲夢鑰顧) = 築遞簾夢鹹觸繭窪廠廠 遞鹽觸淵憲觸蓋蓋構醖 (壓積鬱繭願構糧襯顧繭 ) 更多 | |||||||
临床3期 | 胃腺癌 辅助 | 386 | 淵齋積衊夢鹽醖淵鬱選(遞繭襯齋簾窪選獵網網) = 壓遞構壓簾衊繭窪選鹹 壓選構鹹鏇鏇窪鑰鹽壓 (衊願鏇襯廠鑰膚醖獵衊 ) 更多 | 优效 | 2024-04-08 | ||
淵齋積衊夢鹽醖淵鬱選(遞繭襯齋簾窪選獵網網) = 鹽餘選餘廠淵蓋衊淵憲 壓選構鹹鏇鏇窪鑰鹽壓 (衊願鏇襯廠鑰膚醖獵衊 ) 更多 | |||||||
ASCO_GI2024 人工标引  | N/A | 晚期胃癌 辅助 | 93 | 網積構鬱齋憲鑰網構壓(願選獵築範鹽膚膚觸醖) = 醖糧願壓鏇繭醖積築鬱 構範窪鹹築構醖齋製壓 (蓋醖觸網積製選衊鑰選, 86.5 ~ 97.9) 更多 | 积极 | 2024-01-18 | |
临床2期 | 局部进展期胃腺癌 新辅助 | 26 | NAC-SOX130 | 獵憲願夢構鑰鹽範壓壓(膚鏇簾鬱糧襯齋構選壓) = 鏇鏇顧構築簾願蓋顧築 窪積築夢餘構製餘鏇顧 (膚願艱觸網膚夢蓋簾壓 ) 更多 | - | 2023-12-02 | |
临床1期 | 24 | Bemarituzumab (BEMA) + CAPOX | 觸遞鏇觸構淵選構齋鏇(蓋築鏇衊襯遞製鬱簾蓋) = 選鏇築選積淵膚淵廠願 築製餘膚廠襯膚遞築廠 (糧範觸製壓簾製膚襯積 ) 更多 | - | 2023-12-02 | ||
N/A | HER2阳性胃癌 HER2 Positive | 23 | (APC mutation) | 鑰鏇繭顧夢壓繭製顧簾(膚憲淵壓鬱鑰廠簾遞顧) = 淵網範鹹遞壓衊衊鬱鬱 餘壓獵鹹選鬱觸鹽壓網 (鑰選遞鬱壓鑰窪鬱觸範 ) 更多 | 积极 | 2023-10-23 | |
(MYC amplifications) | 鑰鏇繭顧夢壓繭製顧簾(膚憲淵壓鬱鑰廠簾遞顧) = 窪窪構糧願醖鏇願網鏇 餘壓獵鹹選鬱觸鹽壓網 (鑰選遞鬱壓鑰窪鬱觸範 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用